- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01939730
Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma
Rituximab (IDEC-C2B8) Plus GM-CSF in Patients With Follicular B-Cell Lymphoma
Descripción general del estudio
Descripción detallada
Rituximab seeks out and helps destroy cancer cells. GM-CSF stimulates the body to produce white blood cells.
Before treatment starts, patients will have a complete exam, including blood and urine tests. A chest x-ray and a CT scan or MRI scan of the abdomen and pelvis will be done to measure tumors. Bone marrow and lymph node samples will be taken.
Women who are able to have children must have a negative blood pregnancy test.
Patients in this study will receive both rituximab and GM-CSF. The combined treatment will last 8 weeks.
Rituximab will be given through a needle in a vein over 3-6 hours once a week. GM-CSF will be given through a needle under the skin 3 times a week. The first of these 3 doses will be usually given 1 hour before the rituximab dose. In selected cases, GM-CSF will start 1 week before or 1 day after the rituximab.
Patients may also receive the drugs acetaminophen (Tylenol) and diphenhydramine hydrochloride (Benadryl) 30-60 minutes before each dose of rituximab. This will be done to ease side effects. Patients may need to stay in the clinic for up to 2 hours after rituximab is given.
If the combined Rituximab and GM-CSF treatment causes severe side effects, the treatment may be stopped.
During the study, blood tests will be done before each rituximab treatment and after the first and fourth rituximab treatments. About 2 to 6 teaspoons of blood will be drawn for each test. A physical exam and a urine test will be done before the fourth rituximab treatment.
After all treatment is done, patients will have a complete exam, including blood tests once a week for 4 weeks and then at 2, 3, 6, 9, 12, 18, and 24 months. A CT scan or MRI scan of the abdomen and pelvis will also be done at 2, 3, 6, 9, 12, 18, and 24 months. Bone marrow samples will be taken at 2, 3, and 12 months. Some patients may also have bone marrow samples taken once a year after that. A large needle will be used to take the bone marrow samples.
This is an investigational study. GM-CSF and rituximab are approved for commercial use by FDA. As many as 40 patients will take part in the study. All will be treated as outpatients. The study will take place only at the University of Texas (UT) MD Anderson Cancer Center (MDACC).
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- University of Texas MD Anderson Cancer Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Histologically confirmed follicular B-cell lymphoma. This can include relapsed patients, who have had no prior rituximab therapy, or previously untreated patients. Previously untreated patients should be made aware of higher priority protocols such as combination chemo-immunotherapy protocols, but if they decline that, they can be entered on this protocol.
- Males or females, 18 years or older; expected survival of =/> 4 months; performance status of 0, 1 or 2.
- Demonstrable monoclonal cluster of differentiation antigen 20 (CD20)-positive B-cell population.
- Acceptable hematologic status including:
i. hemoglobin (Hgb) =/> 8.0 gm/dL
ii. White blood count (WBC) =/> 3.0 x 10^3/mm^3(x 10^9/L)
iii. Absolute granulocyte count =/> 1.5 x 10^3/mm^3
iv. Platelet count =/>75 x 10^3/mm^3
e. Adequate renal function (serum creatinine ≤ 2mg/dl)
Exclusion Criteria:
- presence of Central Nervous System (CNS) Lymphoma
- chronic lymphocytic leukemia (CLL)
- small lymphocytic lymphoma
- therapy in prior 3 weeks (6 weeks for nitrosourea; 6 months for Bone Marrow Transplantation (BMT))
- patients who received prior rituximab or other anti-CD20 therapy
- serious non-malignant disease, or other malignancy
- active infection
- history of HIV infection
i pregnancy
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Rituximab + GM-CSF
All patients receive one (1) course of therapy consisting of four (4) doses of rituximab, a single dose 375 mg/m^2 administered once weekly for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly (tiw) for 8 weeks, starting 1 hour before the first dose of rituximab.
In selected cases, the GM-CSF starts 1 week before, or 1 day after, the first rituximab dose.
|
375 mg/m^2 by vein once a week for 4 weeks on Days 1, 8, 15, 22.
Otros nombres:
250 mcg subcutaneously 3 times a week for 8 weeks.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Overall Response Rate of Rituximab plus GM-CSF of repeat doses (once weekly times four)
Periodo de tiempo: 1 month
|
Response Rate is the number of participants with response compared to total.
Response definitions: Complete response (CR) defined as those who achieve a normal state which includes no detectable evidence of disease on x-rays.
Complete response "unconfirmed" (CRu) defined on the basis of minimal residual abnormalities on x-ray such as a residual mass <25% of original measurement with no palpable disease on physical examination.
Partial response (PR) defined as 50-75% reduction in the product of palpable tumor diameters of in the tumor volume measurements by radiologic criteria or any palpable disease such as peripheral node(s) > 1 cm in diameter or palpable abdominal mass with histological evidence of lymphoma cells.
Minor response or failure includes <50% tumor shrinkage, or > 50% but with tumor regrowth between courses.
|
1 month
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Felipe Samaniego, MD, MPH, BS, M.D. Anderson Cancer Center
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del sistema inmunológico
- Neoplasias por tipo histológico
- Neoplasias
- Trastornos linfoproliferativos
- Enfermedades linfáticas
- Trastornos inmunoproliferativos
- Linfoma No Hodgkin
- Linfoma
- Linfoma de células B
- Efectos fisiológicos de las drogas
- Agentes antirreumáticos
- Agentes antineoplásicos
- Factores inmunológicos
- Agentes antineoplásicos inmunológicos
- Rituximab
Otros números de identificación del estudio
- DM98-304
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Rituximab
-
Children's Oncology GroupNational Cancer Institute (NCI)Activo, no reclutandoTrastorno linfoproliferativo posterior al trasplante relacionado con el VEB | Trastorno linfoproliferativo postrasplante monomórfico | Trastorno linfoproliferativo polimórfico postrasplante | Trastorno linfoproliferativo monomórfico recurrente posrasplante | Trastorno linfoproliferativo polimórfico... y otras condicionesEstados Unidos
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)ReclutamientoLinfoma folicular de grado 1 en estadio I de Ann Arbor | Linfoma folicular de grado 2 en estadio I de Ann Arbor | Linfoma folicular de grado 1 en estadio II de Ann Arbor | Linfoma folicular de grado 2 en estadio II de Ann ArborEstados Unidos
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Activo, no reclutandoLinfoma folicular de grado 1 recidivante | Linfoma folicular de grado 2 recidivante | Linfoma de células del manto recidivante | Linfoma recidivante de la zona marginal | Linfoma no Hodgkin de células B refractario | Linfoma de linfocitos pequeños recidivante | Linfoma no Hodgkin de células B recurrente y otras condicionesEstados Unidos
-
National Cancer Institute (NCI)TerminadoLinfoma folicular de grado 1 en estadio III de Ann Arbor | Linfoma folicular de grado 2 en estadio III de Ann Arbor | Linfoma folicular de grado 1 en estadio IV de Ann Arbor | Linfoma folicular de grado 2 en estadio IV de Ann Arbor | Linfoma folicular contiguo grado 3 en estadio II de Ann... y otras condicionesEstados Unidos
-
National Cancer Institute (NCI)Activo, no reclutandoLinfoma de células del manto recidivante | Linfoma no Hodgkin de células B refractario | Linfoma no Hodgkin de células B recurrente | Linfoma de células del manto refractarioEstados Unidos
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Activo, no reclutandoLinfoma de linfocitos pequeños recidivante | Leucemia prolinfocítica | Leucemia linfocítica crónica recurrenteEstados Unidos
-
Mabion SAParexelRetirado
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)ReclutamientoLeucemia linfocítica crónica/linfoma linfocítico de células pequeñasEstados Unidos
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)ReclutamientoLeucemia de células peludas | Leucemia de células peludas recurrenteEstados Unidos
-
Mayo ClinicNational Cancer Institute (NCI)TerminadoLinfoma folicular de grado 1 en estadio I de Ann Arbor | Linfoma folicular de grado 2 en estadio I de Ann Arbor | Linfoma folicular de grado 1 en estadio III de Ann Arbor | Linfoma folicular de grado 2 en estadio III de Ann Arbor | Linfoma folicular de grado 1 en estadio IV de Ann Arbor | Linfoma... y otras condicionesEstados Unidos